ArticleNeurochemistry international2026
Multiplexed neurochemical monitoring reveals glutamate modulates dopamine neurotransmission in the nucleus accumbens.
Article in Neurochemistry international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Dopamine (DA) and glutamate (Glu) play vital roles in cognitive function, motor control, reward systems, and addiction. However, neurotransmitters are typically measured one at a time instead of simultaneously, which would allow a better picture of neurotransmitter interactions. In this study, we multiplexed dopamine detection using fast-scan cyclic voltammetry (FSCV) and glutamate detection using genetically encoded iGluSnFR fluorescent probes to simultaneously investigate dopamine and glutamate signaling in mouse nucleus accumbens slices. We perturbed glutamate transmission to identify how faster synaptic glutamate regulated slower dopamine volume transmission. After bathing brain slices in a buffer containing 100 μM glutamate, dopamine release decreased by nearly half. We then used drugs to inhibit different glutamatergic proteins to test their effects on dopamine release. Blocking the excitatory amino acid transporter (EAAT2) using DL-TBOA (20 μM) increased glutamate concentrations and decreased dopamine release. Blocking metabotropic glutamate receptors (mGluR2/3) with LY 341495 (40 μM) did not affect dopamine release and the mGluR2 agonist LY 379268 (10 μM) also did not affect dopamine release, so the effect was not mediated by metabotropic group 2/3 receptors. Blocking NMDAR with D-AP5 (50 μM) decreased glutamate but did not change dopamine release. Blocking AMPA/kaintate receptor function with NBQX (5 μM) did not change glutamate release but did increase dopamine release. This work demonstrates the importance of simultaneous detection of related neurotransmitters while showing that glutamate and dopamine release have an inverse relationship that is partially mediated by binding to AMPA and Kainate receptors.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.